Nicholas James
Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.
Nicholas James leads STAMPEDE, the multi-arm multi-stage trial that established docetaxel and abiraterone in hormone-sensitive metastatic prostate cancer, and has led trials of chemoradiotherapy in bladder cancer.
| Title | Journal | Year |
|---|---|---|
| Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE) | NEJM | 2017 |
Pages like this
not linked directly; found by shared links- PersonJohann de Bono
Shares STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, Abiraterone acetate, The Institute of Cancer Research, The Royal Marsden.
- TrialPEACE-1
Shares Docetaxel, Abiraterone acetate, Prostate cancer.
- IdeaA perpetual platform trial in every major cancer, funded as infrastructure
Shares STAMPEDE, Basket, umbrella, and platform trials, Bladder & urothelial cancer.
- TrialCHAARTED (E3805)
Shares Docetaxel, Prostate cancer.
- TrialARASENS
Shares Docetaxel, Prostate cancer.
- IdeaA non-profit phase 1b combination unit that any drug owner can use
- TrialPROpel
Shares Abiraterone acetate, Prostate cancer.
- PersonUwe Oelfke